Protara Therapeutics (NASDAQ:TARA – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research note issued to investors on Monday, Benzinga reports. They presently have a $23.00 price target on the stock.
Separately, Oppenheimer raised their target price on shares of Protara Therapeutics from $26.00 to $30.00 and gave the stock an “outperform” rating in a research note on Monday, April 22nd.
Protara Therapeutics Stock Up 0.7 %
Protara Therapeutics (NASDAQ:TARA – Get Free Report) last released its earnings results on Wednesday, March 13th. The company reported ($0.90) EPS for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.13. Analysts expect that Protara Therapeutics will post -3.55 earnings per share for the current fiscal year.
Protara Therapeutics Company Profile
Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
Read More
- Five stocks we like better than Protara Therapeutics
- Insider Buying Explained: What Investors Need to Know
- 3 Value Stocks You Can Buy Before They Become Big
- ESG Stocks, What Investors Should Know
- Chinese Stocks Stage Impressive Rebound
- What is a Death Cross in Stocks?
- Coca-Cola Stock Analysis: Key Insights and Trends
Receive News & Ratings for Protara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.